Roth Capital analyst Kyle Bauser resumed coverage of iRadimed (IRMD) with a Buy rating and $90 price target The firm expects the company to benefit from the launch of its next-gen non-magnetic IV infusion pump. The pump has “significant enhancements” and a premium selling price versus the older version, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: